QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=648DCC623151EB6C1BD56A89A16DA0B0;jsessionid=F643F417C5B131B05933602EC2510AD7;jsessionid=20BA0D640C28CD2190FAF7A86FE23651;jsessionid=40A0F45F57C1E78D5BB2D4622D017268;jsessionid=806D1F15617D3988BE0A6533939CF5BD;jsessionid=2F1403D8D13DDED5667FAC6694C951FB (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
4. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.
5. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=AE4F7F7AAFC4068E9F3136CFBA2A254B;jsessionid=081E2E86E96080529C92C4FB5785CA02;jsessionid=648DCC623151EB6C1BD56A89A16DA0B0;jsessionid=F643F417C5B131B05933602EC2510AD7;jsessionid=20BA0D640C28CD2190FAF7A86FE23651;jsessionid=40A0F45F57C1E78D5BB2D4622D017268;jsessionid=806D1F15617D3988BE0A6533939CF5BD;jsessionid=2F1403D8D13DDED5667FAC6694C951FB